Vector BioPharma is a biopharmaceutical company aiming to transform the safety, efficacy, and specificity of drug delivery, to improve treatments for patients.
Vector BioPharma has raised €29M across 1 funding round, most recently a Series A round in Aug 2022. Based in Basel, Switzerland; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-08-12 | Series A | €29M |
| — |
| View deal → |
